Trial Profile
Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (Aged 18-59) With Acute Myeloid Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 28 Jul 2023 Planned primary completion date changed from 25 Jun 2023 to 25 Jun 2024.
- 16 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 25 Jun 2023.
- 22 Aug 2022 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.